Valuation: Avalo Therapeutics, Inc.

Market Cap 104.85Cr 91Cr 85Cr 78Cr 145.95Cr 10TCr 148.19Cr 1TCr 391.3Cr 5.01TCr 393.66Cr 385.1Cr 17TCr P/E 2026 *
-7.24x
P/E 2027 * -7.33x
Enterprise Value 62Cr 54Cr 51Cr 46Cr 87Cr 5.96TCr 88Cr 596.21Cr 233.06Cr 2.98TCr 234.46Cr 229.37Cr 9.94TCr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.3%
Yield 2026 *
0.06%
Yield 2027 * -
1 day+0.41%
1 week+3.77%
Current month+7.12%
1 month+1.77%
3 months-1.96%
6 months+35.76%
Current year+7.65%
1 week 17.9
Extreme 17.9
20
1 month 17.54
Extreme 17.54
20.01
Current year 12.51
Extreme 12.51
24.27
1 year 8.41
Extreme 8.41
24.27
3 years 3.39
Extreme 3.39
71.04
5 years 3.39
Extreme 3.39
9,331.13
10 years 3.39
Extreme 3.39
22,031.54
Manager TitleAgeSince
Chief Executive Officer 72 14/02/2022
Director of Finance/CFO 42 14/02/2022
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 72 08/08/2022
Director/Board Member 78 12/10/2020
Director/Board Member 55 28/03/2024
Date Insider Type Main position Quantity % Market Cap.
27/07/26 Fiscal year

Chief Technology Officer

3,000 0.0057%
30/06/26 Free

Director

1,080 0.0020%
30/06/26 Fiscal year

Chief Technology Officer

13,962 0.0264%
Change 5-day change 1-year change 3-year change Capi.($)
+0.41%+3.77%+108.87%-36.31% 104.85Cr
-0.73%+7.82%+73.81%+102.34% 7.01TCr
+1.60%+1.66%+37.76%+67.36% 5.49TCr
-0.22%+33.59%+8.43%+489.75% 2.89TCr
-0.35%+10.20%+48.05%+7.17% 2.39TCr
-0.06%+0.61%-16.45%-13.26% 2.33TCr
-1.37%+7.87%+251.71%+464.53% 1.84TCr
+2.21%+7.66%+47.18%-20.09% 1.88TCr
-0.66%+3.35%+25.48%+619.18% 1.61TCr
-1.85%-11.15%+32.75%+134.11% 1.25TCr
Average -0.09%+7.92%+61.76%+181.48% 2.68TCr
Weighted average by Cap. +0.02%+9.41%+54.90%+166.70%

Financials

2026 *2027 *
Net sales - -
Net income -11Cr -9.33Cr -8.74Cr -7.97Cr -15Cr -1.03TCr -15Cr -102.83Cr -40Cr -514.34Cr -40Cr -40Cr -1.72TCr -13Cr -11Cr -10Cr -9.55Cr -18Cr -1.23TCr -18Cr -123.2Cr -48Cr -616.24Cr -48Cr -47Cr -2.05TCr
Net Debt -42Cr -37Cr -34Cr -31Cr -59Cr -4.04TCr -60Cr -404.82Cr -158.24Cr -2.02TCr -159.2Cr -155.74Cr -6.75TCr -31Cr -26Cr -25Cr -23Cr -43Cr -2.91TCr -43Cr -291.73Cr -114.03Cr -1.46TCr -114.72Cr -112.23Cr -4.87TCr
Logo Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL- 1β is a central driver in the inflammatory process. Quisovalimab is a fully human monoclonal antibody (mAb), directed against human LIGHT (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. AVTX-008 is differentiated by having specific binding to BTLA, with no binding to LIGHT or CD160.
Employees
33
Date Price Change Volume
12/26/12 $19.55 +0.41% 3,17,250
11/26/11 $19.47 -1.52% 7,14,965
10/26/10 $19.77 +7.91% 9,77,859
07/26/07 $18.32 -2.03% 7,30,255
06/26/06 $18.70 -0.74% 5,96,213
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
19.55USD
Average target price
44.15USD
Spread / Average Target
+125.85%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AVTX Stock